Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

被引：86

作者：

Yang, Yunpeng ^{[1
]}

Pan, Jianji ^{[2
]}

Wang, Hui ^{[3
]}

Zhao, Yuanyuan ^{[1
]}

Qu, Shenhong ^{[4
]}

Chen, Nianyong ^{[5
,6
]}

Chen, Xiaozhong ^{[7
]}

Sun, Yan ^{[8
]}

He, Xiaohui ^{[9
]}

Hu, Chaosu ^{[10
]}

Lin, Lizhu ^{[11
]}

Yu, Qitao ^{[12
]}

Wang, Siyang ^{[13
]}

Wang, Guihua ^{[14
]}

Lei, Feng ^{[15
]}

Wen, Jiyu ^{[16
]}

Yang, Kunyu ^{[17
]}

Lin, Zhixiong ^{[18
]}

Guo, Ye ^{[19
]}

Chen, Shaoqing ^{[20
]}

Huang, Xiaoming ^{[21
]}

Wu, Yanjie ^{[22
]}

Liang, Liang ^{[23
]}

Chen, Chenqi ^{[22
]}

Bai, Fan ^{[22
]}

Ma, Xiaopeng ^{[24
]}

Zhang, Yun ^{[23
]}

Leaw, Shiangjiin ^{[22
]}

Zhang, Li ^{[1
]}

Fang, Wenfeng ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol Sun Yat, State Key Lab Oncol South China,Canc Ctr,Guangdong, 16th Floor,2 Bldg,Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China

[2] Fujian Canc Hosp, Dept Head & Neck Radiat Oncol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China

[3] Hunan Canc Hosp, Thorac Radiotherapy Dept 1, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

[4] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Canc Res Inst, Otolaryngol Dept, 6 Tao Yuan Rd, Nanning 530021, Guangxi, Peoples R China

[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[6] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[7] Zhejiang Canc Hosp, Dept Head & Neck Radiotherapy, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China

[8] Beijing Canc Hosp, Radiotherapy Dept, 52 Fucheng Rd, Beijing 100142, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, 17 Panjiayuannanli, Beijing 100021, Peoples R China

[10] Fudan Univ, Shanghai Canc Ctr, Dept Radiat, 270 Dongan Rd, Shanghai 200032, Peoples R China

[11] Guangzhou Tradit Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, 16 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China

[12] Guangxi Med Univ, Affiliated Canc Hosp, Dept Med Oncol Resp, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China

[13] Sun Yat Sen Univ, Affiliated Hosp 5, Head & Neck Oncol Sect 1, 52 Meihua East Rd, Zhuhai 519000, Peoples R China

[14] Changsha Cent Hosp, Dept Oncol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China

[15] Peoples Hosp Zhongshan City, Head & Neck Radiotherapy Dept, 2 Sunwen East Rd, Zhongshan 528403, Guangdong, Peoples R China

[16] Guangdong Med Univ, Affiliated Hosp, Canc Ctr, Nasopharyngeal Canc Dis Ctr, 57 South Renmin Rd, Zhanjiang 524000, Guangdong, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China

[18] Shantou Univ, Canc Hosp, Med Coll, Dept Radiat, 7 Raoping Rd, Shantou 515031, Guangdong, Peoples R China

[19] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China

[21] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Otolaryngol Head & Neck Surg, 107 Yan Jiang West Rd, Guangzhou 510120, Guangdong, Peoples R China

[22] BeiGene Shanghai Co Ltd, Jing Kerry Ctr, Clin Dev, 20-F,Tower 3,1228 Middle Yanan Rd, Shanghai 200040, Peoples R China

[23] BeiGene Beijing Co Ltd, Clin Biomarker Sci & CDx Dev, 6 Jianguomenwai Ave,SK Tower,36th Floor, Beijing 100022, Peoples R China

[24] BeiGene Beijing Co Ltd, Bioinformat, 30 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China

来源：

CANCER CELL | 2023年 / 41卷 / 06期

关键词：

biomarker; clinical trial; double-blinded; gene expression profiling; immunotherapy; nasopharyngeal carcinoma; PD-1; inhibitor; randomized; tislelizumab;

D O I：

10.1016/j.ccell.2023.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo -chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumabchemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically "hot"tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.

引用

页码：1061 / +

页数：17

共 50 条

[1] RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.
Zhang, Li
Yang, Yunpeng
Pan, Jian-Ji
Chen, Xiaozhong
Sun, Yan
Wang, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
[2] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
Pei, Zhengda
Xiao, Ningping
Yang, Pei
FRONTIERS IN PHARMACOLOGY, 2023, 14
[3] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Lu, Shun
Wang, Jie
Yu, Yan
Yu, Xinmin
Hu, Yanping
Ai, Xinghao
Ma, Zhiyong
Li, Xingya
Zhuang, Wu
Liu, Yunpeng
Li, Weidong
Cui, Jiuwei
Wang, Dong
Liao, Wangjun
Zhou, Jianying
Wang, Zhehai
Sun, Yuping
Qiu, Xiusong
Gao, Jie
Bao, Yuanyuan
Liang, Liang
Wang, Mengzhao
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
[4] RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine plus cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Yang, Y.
Pan, J.
Wang, H.
Qu, S.
Chen, N.
Chen, X.
Sun, Y.
He, X.
Hu, C.
Lin, L.
Yu, Q.
Wang, S.
Wang, G.
Lei, F.
Wen, J.
Yang, K.
Lin, Z.
Wu, Y.
Fang, W.
Zhang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S1430 - S1430
[5] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai
Qiu-Yan Chen
Dongping Chen
Chaosu Hu
Kunyu Yang
Jiyu Wen
Jingao Li
Ying-Rui Shi
Feng Jin
Ruilian Xu
Jianji Pan
Shenhong Qu
Ping Li
Chunhong Hu
Yi-Chun Liu
Yi Jiang
Xia He
Hung-Ming Wang
Wan-Teck Lim
Wangjun Liao
Xiaohui He
Xiaozhong Chen
Zhigang Liu
Xianglin Yuan
Qi Li
Xiaoyan Lin
Shanghua Jing
Yanju Chen
Yin Lu
Ching-Yun Hsieh
Muh-Hwa Yang
Chia-Jui Yen
Jens Samol
Hui Feng
Sheng Yao
Patricia Keegan
Rui-Hua Xu
Nature Medicine, 2021, 27 : 1536 - 1543
[6] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dongping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jingao
Shi, Ying-Rui
Jin, Feng
Xu, Ruilian
Pan, Jianji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Wan-Teck
Liao, Wangjun
He, Xiaohui
Chen, Xiaozhong
Liu, Zhigang
Yuan, Xianglin
Li, Qi
Lin, Xiaoyan
Jing, Shanghua
Chen, Yanju
Lu, Yin
Hsieh, Ching-Yun
Yang, Muh-Hwa
Yen, Chia-Jui
Samol, Jens
Feng, Hui
Yao, Sheng
Keegan, Patricia
Xu, Rui-Hua
NATURE MEDICINE, 2021, 27 (09) : 1536 - +
[7] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
Fang, W. F.
Pan, J.
Wang, H.
Qu, S.
Chen, N.
Chen, X.
Sun, Y.
He, X.
Hu, C.
Lin, L.
Yen, C. J.
Wu, Y.
Yuan, S.
Chen, C.
Yang, Y.
Lean, S.
Zhang, L.
ANNALS OF ONCOLOGY, 2024, 35 : S1554 - S1555
[8] RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Yang, Y.
Pan, J.
Chen, N.
Wu, Y.
Leaw, S.
Bai, F.
Wang, Y.
Zhao, N.
Tang, B.
Barnes, G.
ANNALS OF ONCOLOGY, 2022, 33 : S1521 - S1521
[9] Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.
Jiang, Wei
Liang, Jinghui
Pan, Yufei
Ruan, Xiaolan
Cai, Rui
He, Zhuokai
Chen, Qiuqiu
Zhang, Rongjun
Yang, Xi
Liu, Meilian
Zhao, Bo
Liu, Zhengchun
Niu, Zhijie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC
Wang, Y.
Shi, H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S396 - S396

← 1 2 3 4 5 →